Yassmin Moatasim

Dr. Yassmin Moatasim

water pollution, National Research Center, Giza, Al Jīzah, Egypt
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2013 in Eurosurveillance
Verified
Journal Article
Open access
Ranawaka A.P.M PereraRanawaka A.P.M Perera
Ranawaka A.P.M Perera
PWPei-Gang Wang
Pei-Gang Wang
MGMokhtar Gomaa
Mokhtar Gomaa
Rabeh El-SheshenyRabeh El-Shesheny
Rabeh El-Shesheny
Ahmed KandeilAhmed Kandeil
Ahmed Kandeil
GKG Kayali
G Kayali
We describe a novel spike pseudoparticle neutralisation assay (ppNT) for seroepidemiological studies on Middle East respiratory syndrome coronavirus (MERS-CoV) and apply this assay together with conventional microneutralisation (MN) tests to investigate 1,343 human and 625 animal sera. The sera were collected in Egypt as a region adjacent to areas where MERS has been described, and in Hong Kong, China as a control region. Sera from dromedary camels had a high prevalence of antibody reactive to MERS-CoV by MERS NT (93.6%) and MERS ppNT (98.2%) assay. The antibody titres ranged up to 1,280 and higher in MN assays and 10,240 and higher in ppNT assays. No other investigated species had any antibody reactivity to MERS-CoV. While seropositivity does not exclude the possibility of infection with a closely related virus, our data highlight the need to attempt detection of MERS-CoV or related coronaviruses in dromedary camels. The data show excellent correlation between the conventional MN assay and the novel ppNT assay. The newly developed ppNT assay does not require Biosafety Level 3 containment and is thus a relatively high-throughput assay, well suited for large-scale seroepidemiology studies which are needed to better understand the ecology and epidemiology of MERS-CoV.

4 December 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Ahmed MostafaAhmed Mostafa
Ahmed Mostafa
Ahmed KandeilAhmed Kandeil
Ahmed Kandeil
YEYaseen Elshaier
Yaseen Elshaier
OKOmnia Kutkat
Omnia Kutkat
YMYassmin Moatasim
Yassmin Moatasim
NCNational Centre
National Centre
(1) Background: Drug repositioning is an unconventional drug discovery approach to explore new therapeutic benefits of existing drugs. Currently, it emerges as a rapid avenue to alleviate the COVID-19 pandemic disease. (2) Methods: Herein, we tested the antiviral activity of anti-microbial and anti-inflammatory Food and Drug Administration (FDA)-approved drugs, commonly prescribed to relieve respiratory symptoms, against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the viral causative agent of the COVID-19 pandemic. (3) Results: Of these FDA-approved antimicrobial drugs, Azithromycin, Niclosamide, and Nitazoxanide showed a promising ability to hinder the replication of a SARS-CoV-2 isolate, with IC50 of 0.32, 0.16, and 1.29 µM, respectively. We provided evidence that several antihistamine and anti-inflammatory drugs could partially reduce SARS-CoV-2 replication in vitro. Furthermore, this study showed that Azithromycin can selectively impair SARS-CoV-2 replication, but not the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). A virtual screening study illustrated that Azithromycin, Niclosamide, and Nitazoxanide bind to the main protease of SARS-CoV-2 (Protein data bank (PDB) ID: 6lu7) in binding mode similar to the reported co-crystalized ligand. Also, Niclosamide displayed hydrogen bond (HB) interaction with the key peptide moiety GLN: 493A of the spike glycoprotein active site. (4) Conclusions: The results suggest that Piroxicam should be prescribed in combination with Azithromycin for COVID-19 patients.

1 September 2021 in Bioorganic Chemistry
Verified
Journal Article
Closed access
ISIsraa A. Seliem
Israa A. Seliem
Siva S. PandaSiva S. Panda
Siva S. Panda
AGAdel S. Girgis
Adel S. Girgis
YMYassmin Moatasim
Yassmin Moatasim
AKAhmed Kandeil
Ahmed Kandeil
AAAmany M.M. Al-Mahmoudy
Amany M.M. Al-Mahmoudy

1 April 2014 in Emerging Infectious Diseases
Verified
Journal Article
Open access
GKGhazi Kayali
Ghazi Kayali
Ahmed KandeilAhmed Kandeil
Ahmed Kandeil
Rabeh El-SheshenyRabeh El-Shesheny
Rabeh El-Shesheny
AKAhmed S. Kayed
Ahmed S. Kayed
MGMokhtar Gomaa
Mokhtar Gomaa
NCNational Centre
National Centre
Continuous circulation of influenza A(H5N1) virus among poultry in Egypt has created an epicenter in which the viruses evolve into newer subclades and continue to cause disease in humans. To detect influenza viruses in Egypt, since 2009 we have actively surveyed various regions and poultry production sectors. From August 2010 through January 2013, >11,000 swab samples were collected; 10% were positive by matrix gene reverse transcription PCR. During this period, subtype H9N2 viruses emerged, cocirculated with subtype H5N1 viruses, and frequently co-infected the same avian host. Genetic and antigenic analyses of viruses revealed that influenza A(H5N1) clade 2.2.1 viruses are dominant and that all subtype H9N2 viruses are G1-like. Cocirculation of different subtypes poses concern for potential reassortment. Avian influenza continues to threaten public and animal health in Egypt, and continuous surveillance for avian influenza virus is needed.

15 June 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
Ahmed KandeilAhmed Kandeil
Ahmed Kandeil
Ahmed MostafaAhmed Mostafa
Ahmed Mostafa
OKOmnia Kutkat
Omnia Kutkat
YMYassmin Moatasim
Yassmin Moatasim
Ahmed A. Al-KarmalawyAhmed A. Al-Karmalawy
Ahmed A. Al-Karmalawy
NCNational Centre
National Centre
Until now, there has been no direct evidence of the effectiveness of repurposed FDA-approved drugs against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. Although curcumin, hesperidin, and quercetin have broad spectra of pharmacological properties, their antiviral activities against SARS-CoV-2 remain unclear. Our study aimed to assess the in vitro antiviral activities of curcumin, hesperidin, and quercetin against SARS-CoV-2 compared to hydroxychloroquine and determine their mode of action. In Vero E6 cells, these compounds significantly inhibited virus replication, mainly as virucidal agents primarily indicating their potential activity at the early stage of viral infection. To investigate the mechanism of action of the tested compounds, molecular docking studies were carried out against both SARS-CoV-2 spike (S) and main protease (Mpro) receptors. Collectively, the obtained in silico and in vitro findings suggest that the compounds could be promising SARS-CoV-2 Mpro inhibitors. We recommend further preclinical and clinical studies on the studied compounds to find a potential therapeutic targeting COVID-19 in the near future.

3 July 2014 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
Ahmed KandeilAhmed Kandeil
Ahmed Kandeil
Rabeh El-SheshenyRabeh El-Shesheny
Rabeh El-Shesheny
AMAsmaa M. Maatouq
Asmaa M. Maatouq
YMYassmin Moatasim
Yassmin Moatasim
MSMahmoud M. Shehata
Mahmoud M. Shehata
GKGhazi Kayali
Ghazi Kayali